STRYKER ($SYK) Releases Q3 2026 Earnings
STRYKER ($SYK) reported Q3 2026 earnings of $3.52 per share, missing estimates by $0.06, with revenue of $6.52B, missing estimates by $168.19M. Stock price fell 5.83%. Insiders sold shares, while hedge funds had mixed activity. Analysts' price targets range from $330 to $407.
How this was made
The 30-second read
Why it matters
The immediate trading signal is the dual miss (EPS and revenue) versus estimates, which typically leads to estimate cuts and multiple compression until management commentary/guidance clarifies durability.
Market read
Traders can use the reported miss versus consensus to reassess near-term expectations and position for follow-on analyst revisions.
What to watch
No forward guidance, backlog, or management commentary is included, so traders may be missing the key driver of whether the miss is temporary versus structural.
Background
This is an earnings release writeup for Stryker’s Q3 2026 results, including EPS and revenue versus consensus and a same-day price reaction.
Ticker impact
Stryker reported Q3 2026 EPS of $3.52, missing $3.58, and revenue of $6.52B, below $6.69B, with the stock down 5.83% since close.
Likely pressure as the market digests the EPS and revenue shortfalls and adjusts forward estimates.
The article provides the company’s own quarterly results versus estimates and notes a same-day post-close decline of 5.83%, indicating immediate market reaction to the miss.
Market effects
As a large medical device name, the miss can modestly weigh on sentiment for medtech earnings expectations, though no sector-wide guidance is provided here.
Primarily US large-cap medtech sentiment; no regional macro or policy linkage is described.
Limited global spillover indicated, since the article contains only company-specific results and insider/13F-style flows.
Counterpoint
The article does not include guidance, margins, or segment detail; the stock drop may overreact if the miss is driven by timing or one-off items not captured here.
Key entities
- companyStryker
Reported Q3 2026 EPS of $3.52 (vs $3.58 estimate) and revenue of $6.52B (vs $6.69B estimate), with shares down 5.83% since close.
